Cingulate Inc. (CING)Healthcare | Biotechnology | Kansas City, United States | NasdaqCM
4.68 USD
-0.23
(-4.684%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:17 a.m. EDT
The investment case for Cingulate is currently broken by a catastrophic multi-year decline. The stock has lost nearly 99% of its value over the last three years, with every single year showing negative returns. While the company possesses a promising ADHD drug candidate and has recently joined the Russell 3000E index, the market has priced in severe structural deterioration, likely due to the massive drop in share count following the split from its parent entity. Fundamentally, the business is burning cash with negative free cash flow and no dividends to support shareholders. The options market confirms this pessimism, with traders pouring capital into deep out-of-the-money puts to hedge against further collapse. Despite the lofty analyst price targets which ignore the reality of the delisting risk and dilution, the data suggests a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.077002 |
| AutoARIMA | 0.084463 |
| AutoETS | 0.100236 |
| MSTL | 0.105734 |
| MSTL_55 | 0.155355 |
| MSTL_77 | 0.162991 |
| MSTL_55_77 | 0.210099 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 3.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.234 |
| Excess Kurtosis | 0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 39.38 |
| Market Cap | 63,035,088 |
| Forward P/E | -6.32 |
| Beta | -0.92 |
| Website | https://www.cingulate.com |
As of July 11, 2026, 6:17 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive put volume and open interest at the $2.50 strike across multiple expirations, particularly in August and November. This 'new flow' indicates a strong hedging or bearish bet against further declines. Conversely, call activity is negligible and concentrated near the money, suggesting a lack of speculative bullish conviction despite the elevated implied volatility which reflects fear rather than expected upside.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.035398245 |
| Address1 | 1,901 West 47th Place |
| All Time High | 1,236.0 |
| All Time Low | 1.8 |
| Ask | 5.84 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 387,090 |
| Average Daily Volume3 Month | 563,606 |
| Average Volume | 563,606 |
| Average Volume10Days | 387,090 |
| Beta | -0.915 |
| Bid | 3.45 |
| Bid Size | 2 |
| Book Value | 1.584 |
| City | Kansas City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.68 |
| Current Ratio | 2.547 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.9 |
| Day Low | 4.51 |
| Debt To Equity | 39.38 |
| Display Name | Cingulate |
| Ebitda | -23,658,508 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.846 |
| Enterprise Value | 43,667,564 |
| Eps Current Year | -2.3 |
| Eps Forward | -0.74 |
| Eps Trailing Twelve Months | -4.33 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8383 |
| Fifty Day Average Change | -0.1583004 |
| Fifty Day Average Change Percent | -0.032718185 |
| Fifty Two Week Change Percent | 3.5398245 |
| Fifty Two Week High | 11.89 |
| Fifty Two Week High Change | -7.2100005 |
| Fifty Two Week High Change Percent | -0.60639197 |
| Fifty Two Week Low | 3.16 |
| Fifty Two Week Low Change | 1.5199997 |
| Fifty Two Week Low Change Percent | 0.48101255 |
| Fifty Two Week Range | 3.16 - 11.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,638,973,800,000 |
| Float Shares | 12,944,387 |
| Forward Eps | -0.74 |
| Forward P E | -6.324324 |
| Free Cashflow | -11,919,704 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -9,735,749 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.30539 |
| Held Percent Institutions | 0.08859 |
| Implied Shares Outstanding | 13,469,036 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-08 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,161,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. |
| Long Name | Cingulate Inc. |
| Market | us_market |
| Market Cap | 63,035,088 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1674914781 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -27,909,322 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 63,035,088 |
| Number Of Analyst Opinions | 5 |
| Open | 4.9 |
| Operating Cashflow | -19,549,860 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 913 942 2300 |
| Pre Market Change | 0.01999998 |
| Pre Market Change Percent | 0.42735004 |
| Pre Market Price | 4.7 |
| Pre Market Time | 1,784,027,982 |
| Previous Close | 4.91 |
| Price Eps Current Year | -2.0347826 |
| Price Hint | 4 |
| Price To Book | 2.9545453 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.373 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.23 |
| Regular Market Change Percent | -4.68432 |
| Regular Market Day High | 4.9 |
| Regular Market Day Low | 4.51 |
| Regular Market Day Range | 4.51 - 4.9 |
| Regular Market Open | 4.9 |
| Regular Market Previous Close | 4.91 |
| Regular Market Price | 4.68 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 345,882 |
| Return On Assets | -0.69682 |
| Return On Equity | -2.2511399 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 13,469,036 |
| Shares Percent Shares Out | 0.1021 |
| Shares Short | 1,375,106 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,959,020 |
| Short Name | Cingulate Inc. |
| Short Percent Of Float | 0.1471 |
| Short Ratio | 2.02 |
| Source Interval | 15 |
| State | KS |
| Symbol | CING |
| Target High Price | 52.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 23.0 |
| Target Median Price | 20.0 |
| Total Cash | 25,893,210 |
| Total Cash Per Share | 1.95 |
| Total Debt | 7,428,991 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.047975 |
| Two Hundred Day Average Change | -0.36797523 |
| Two Hundred Day Average Change Percent | -0.07289562 |
| Type Disp | Equity |
| Volume | 345,882 |
| Website | https://www.cingulate.com |
| Zip | 66,205 |